DERM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Journey Medical Corp (DERM) is not a strong buy for a beginner, long-term investor at this time. The lack of positive trading signals, weak financial performance, and absence of significant positive catalysts make it prudent to hold off on investing in this stock currently.
The stock's MACD is negatively expanding, RSI is neutral at 32.933, and moving averages are converging, indicating no clear bullish momentum. The stock is trading near its support level (S1: 7.889) but below the pivot point (8.382). Short-term trends suggest a potential decline of -1.85% over the next week.
NULL identified. No recent news or significant insider/hedge fund activity. The company has a chance to improve its financials in the upcoming earnings report on March 19, 2026.
Weak financial performance in Q3 2025, with net income dropping by -3.14% YoY and EPS declining by -25%. Gross margin also fell by -3.99%. No recent congress trading data or influential figure activity. Technical indicators do not suggest a bullish trend.
In Q3 2025, revenue increased by 20.52% YoY to $17.63M, but net income dropped to -$2.315M (-3.14% YoY), and EPS fell to -0.09 (-25% YoY). Gross margin declined to 61.32% (-3.99% YoY), indicating cost pressures.
No analyst rating or price target data available.
